Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users - A prospective randomized trial

被引:67
|
作者
Curtis, Jeffrey R.
Westfall, Andrew O.
Allison, Jeroan
Becker, Angela
Melton, Mary Elkins
Freeman, Allison
Kiefe, Catarina I.
MacArthur, Marilyn
Ockershausen, Theresa
Stewart, Emily
Weissman, Norm
Saag, Kenneth G.
机构
[1] Univ Alabama, Ctr Educ & Res Therapeut Musculoskeletal Dis, Birmingham, AL 35294 USA
[2] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA
[3] Univ Alabama, Div Prevent Med, Dept Med, Birmingham, AL 35294 USA
[4] Vet Affairs Med Ctr, Birmingham, AL 35294 USA
[5] Aetna Integrated Informat, Blue Bell, PA USA
关键词
D O I
10.1001/archinte.167.6.591
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In light of widespread undertreatment for glucocorticoid-induced osteoporosis (GIOP), we designed a group randomized controlled trial to increase bone mineral density (BMD) testing and osteoporosis medication prescribing among patients receiving long-term glucocorticoid therapy. Methods: Using administrative databases of a large US health plan, we identified physicians who prescribed long-term glucocorticoid therapy to at least 3 patients. One hundred fifty-three participating physicians were randomized to receive a 3-module Web-based GIOP intervention or control course. Intervention modules focused on GIOP management and incorporated case-based continuing medical education and personalized audit and feedback of GIOP management compared with that of the top 10% of study physicians. In the year following the intervention, we compared rates of BMD testing and osteoporosis medication prescribing between intervention and control physicians. Results: Following the intervention, intent-to-treat analyses showed that 78 intervention physicians (472 patients) vs 75 control physicians (477 patients) had similar rates of BMD testing (19% vs 21%, P=.48; rate difference, -2%; 95% confidence interval [CI], -8% to 4%) and osteoporosis medication prescribing (32% vs 29%, P=.34; rate difference, 3%; 95% CI, -3% to 9%). Among 45 physicians completing all modules (343 patients), intervention physicians had numerically but not significantly higher rates of BMD testing (26% vs 16%, P=.04; rate difference, 10%; 95% CI, 1%-20%) and bis-phosphonate prescribing (24% vs 17%, P=.09; rate difference, 7%; 95% CI, -1% to 16%) or met a combined end point of BMD testing or osteoporosis medication prescribing (54% vs 44%, P=.07; rate difference, 10%; 95% Cl, -1% to 21%) compared with control physicians. Conclusions: In the main analysis, a Web-based intervention incorporating performance audit and feedback and case-based continuing medical education had no significant effect on the quality of osteoporosis care. However, dose-response trends showed that physicians with greater exposure to the intervention had higher rates of GIOP management. New cost-effective modalities are needed to improve the quality of osteoporosis care.
引用
收藏
页码:591 / 596
页数:6
相关论文
共 50 条
  • [1] Challenges in improving quality of osteoporosis care for long term glucocorticoid users.
    Curtis, Jeffrey R.
    Westfall, Andrew O.
    Allison, Jeroan J.
    Becker, Angela
    MacArthur, Marilyn
    Ockerhurst, Theresa
    Stewart, Emily
    Weissman, Norman
    Saag, Kenneth G.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S85 - S85
  • [2] Improving quality of osteoporosis care for long term glucocorticoid users.
    Curtis, J. R.
    Westfall, A. O.
    Allison, J. J.
    Becker, A.
    MacArthur, M.
    Ockershausen, T.
    Stewart, E.
    Weissman, N.
    Saag, K. G.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S420 - S420
  • [3] Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial
    Mok, Chi Chiu
    Ho, Ling Yin
    Ma, Kwok Man
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [4] DENOSUMAB VERSUS ORAL BISPHOSPHONATE FOR OSTEOPOROSIS IN LONG-TERM GLUCOCORTICOID USERS: A 12-MONTH RANDOMIZED CONTROLLED TRIAL
    Mok, C. C.
    Ho, L. Y.
    Chan, K. L.
    Tse, S. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1190 - 1190
  • [5] Improving the Quality of Long-Term Care
    Silvestre, Josephine H.
    Bowers, Barbara J.
    Gaard, Sue
    [J]. JOURNAL OF NURSING REGULATION, 2015, 6 (02) : 52 - 56
  • [6] Improving the quality of long-term care
    Cohen, ES
    [J]. GERONTOLOGIST, 2004, 44 (01): : 127 - 134
  • [7] Improving quality of long-term care
    Ray, WA
    [J]. MEDICAL CARE, 2000, 38 (12) : 1151 - 1153
  • [8] Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial
    Mok, Chi Chiu
    Ho, Ling Yin
    Leung, Stella Mei Tik
    Cheung, Hoi Ning
    Chen, Sammy Pak Lam
    Ma, Kwok Man
    [J]. BONE, 2021, 146
  • [9] Improving quality of care in osteoporosis: Opportunities and challenges
    Teng G.G.
    Warriner A.
    Curtis J.R.
    Saag K.G.
    [J]. Current Rheumatology Reports, 2008, 10 (2) : 123 - 130
  • [10] Challenges in defining and improving osteoporosis quality of care
    Warriner, A.
    Curtis, J. R.
    Saag, K. G.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (06) : S142 - S146